2364-9534

AAPS Open

Springer (Biomed Central Ltd.)

View prefix report (10.1186)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 66 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact66 DOIs
2

Attach ORCID iDs across 64 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact64 DOIs
3

Deposit reference lists for 5 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact5 DOIs

DOIs for this ISSN

Showing the top 5 of 174 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Scope and relevance of a pulmonary biopharmaceutical classif… (10.1186/s41120-015-0002-x)
Abstract ORCID
96.72 85
2 Solid form changes during drug development: good, bad, and u… (10.1186/s41120-016-0003-4)
Abstract ORCID
88.17 57
3 Oral nanoemulsions of candesartan cilexetil: formulation, ch… (10.1186/s41120-017-0016-7)
Abstract ORCID
87.79 56
4 ANVISA: an introduction to a new regulatory agency with many… (10.1186/s41120-018-0029-x)
Abstract ORCID
71.57 26
5 Oral solid self-nanoemulsifying drug delivery systems of can… (10.1186/s41120-017-0015-8)
Abstract ORCID
69.90 24
6 Considerations and recommendations on traditional and non-tr… (10.1186/s41120-016-0004-3)
Abstract ORCID
60.21 15
7 A review of in vivo and in vitro aspects of alcohol-induced… (10.1186/s41120-017-0014-9)
Abstract ORCID
60.21 15
8 New directions in pharmaceutical amorphous materials and amo… (10.1186/s41120-017-0017-6)
Abstract ORCID
57.31 13
9 AAPS Workshop: accelerating pharmaceutical development throu… (10.1186/s41120-017-0018-5)
Abstract ORCID
57.31 13
10 Plasma modification of microporous polymer membranes for app… (10.1186/s41120-017-0019-4)
Abstract ORCID
57.31 13
11 Erratum to: Scope and relevance of a pulmonary biopharmaceut… (10.1186/s41120-016-0005-2)
Abstract ORCID
45.15 7
12 Stability challenges not addressed by harmonized guidance –… (10.1186/s41120-018-0022-4)
Abstract ORCID
45.15 7
13 Development and evaluation of taste masked dry syrup formula… (10.1186/s41120-019-0030-z)
Abstract ORCID
45.15 7
14 Safety and pharmacokinetics of a highly bioavailable resvera… (10.1186/s41120-022-00058-1)
ORCID
40.58 41
15 Developing key performance indicators to measure the progres… (10.1186/s41120-018-0024-2)
Abstract ORCID
38.91 5
16 Improving the safety of disposable auto-injection devices: a… (10.1186/s41120-018-0027-z)
Abstract
36.56 28
17 Comparison of rates of nausea side effects for prescription… (10.1186/s41120-017-0020-y)
Abstract ORCID
34.95 4
18 Drug manufacturing and access to medicines: the West African… (10.1186/s41120-019-0032-x)
Abstract
34.95 24
19 Substandard and falsified medicine screening technologies (10.1186/s41120-019-0031-y)
Abstract
34.51 23
20 Prediction of the changes in drug dissolution from an immedi… (10.1186/s41120-016-0010-5)
Abstract
34.04 22
21 A review on lipid-based nanocarriers mimicking chylomicron a… (10.1186/s41120-023-00080-x)
ORCID
33.06 20
22 Best practices for the development and fit-for-purpose valid… (10.1186/s41120-021-00050-1)
ORCID
31.38 17
23 Structured content and data management—enhancing acceleratio… (10.1186/s41120-023-00077-6)
ORCID
30.76 16
24 Nano-formulations composed of cell membrane-specific cellula… (10.1186/s41120-018-0025-1)
Abstract ORCID
30.10 3
25 Effect of chemical penetration enhancers on the transdermal… (10.1186/s41120-024-00092-1)
ORCID
30.10 15
26 An industrial case study: QbD to accelerate time-to-market o… (10.1186/s41120-021-00047-w)
ORCID
29.40 14
27 Preparation of O/W nano-emulsion containing nettle and fenug… (10.1186/s41120-021-00046-x)
ORCID
28.65 13
28 Customer-centric product presentations for monoclonal antibo… (10.1186/s41120-022-00069-y)
ORCID
27.85 12
29 Scientific and regulatory approaches to confirm quality and… (10.1186/s41120-016-0008-z)
Abstract
26.98 11
30 Transdermal drug delivery system of lidocaine hydrochloride… (10.1186/s41120-023-00074-9)
ORCID
26.98 11
31 Molecular docking assisted exploration on solubilization of… (10.1186/s41120-022-00054-5)
ORCID
25.00 9
32 Analytical approaches to ensure product quality -- AAPS Join… (10.1186/s41120-017-0011-z)
Abstract ORCID
23.86 2
33 Non-isothermal stability by linear heating: a fast method fo… (10.1186/s41120-017-0012-y)
Abstract ORCID
23.86 2
34 Self-microemulsifying system of an ethanolic extract of Heli… (10.1186/s41120-023-00086-5)
ORCID
23.86 8
35 Organoid intelligence: training lab-grown mini-brains to lea… (10.1186/s41120-025-00109-3)
Abstract ORCID
23.86 2
36 Dawn of a new beginning (10.1186/s41120-021-00035-0)
Abstract References ORCID
22.58 1
37 Pharmacokinetic and pharmacodynamic analyses of terlipressin… (10.1186/s41120-022-00052-7)
ORCID
22.58 7
38 Technical transfer and commercialisation of lyophilised biop… (10.1186/s41120-022-00059-0)
ORCID
21.13 6
39 Results from in vitro and in vivo studies evaluating the bio… (10.1186/s41120-022-00063-4)
ORCID
21.13 6
40 Assessment of clinical immunogenicity of inotuzumab ozogamic… (10.1186/s41120-018-0021-5)
Abstract
19.45 5
41 Research on Pickering emulsification technology based on the… (10.1186/s41120-022-00068-z)
ORCID
19.45 5
42 Antibody-drug conjugates: integrated bioanalytical and biodi… (10.1186/s41120-018-0026-0)
Abstract
17.47 4
43 A competitive ligand-binding assay for the detection of neut… (10.1186/s41120-021-00039-w)
ORCID
17.47 4
44 Recent trends in pharmaceutical freeze-drying and control st… (10.1186/s41120-025-00132-4)
ORCID
17.47 4
45 Development of an algorithm to identify mass production cand… (10.1186/s41120-016-0009-y)
Abstract
15.05 3
46 Relative bioavailability of diazoxide, manufactured at two d… (10.1186/s41120-017-0013-x)
Abstract ORCID
15.05 1
47 Utilizing cross-product prior knowledge to rapidly de-risk c… (10.1186/s41120-022-00057-2)
ORCID
15.05 3
48 An in-silico approach towards multivariate acceptable ranges… (10.1186/s41120-024-00095-y)
ORCID
15.05 3
49 Advancements in regulatory agility, regional collaboration,… (10.1186/s41120-024-00102-2)
ORCID
15.05 3
50 A bridging assay for detection and characterization of anti-… (10.1186/s41120-021-00045-y)
ORCID
11.93 2